scholarly journals Prognosis of colorectal cancer in Tikur Anbessa Specialized Hospital, the only oncology center in Ethiopia

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0246424
Author(s):  
Eyob Kebede Etissa ◽  
Mathewos Assefa ◽  
Birhanu Teshome Ayele
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Adjuvant Therapy ◽  
Survival Time ◽  
Cancer Patients ◽  
Addis Ababa ◽  
Metastatic Cancer ◽  
Risk Of Death ◽  
Increased Risk

Introduction Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females worldwide. According to the Addis Ababa cancer registry, it is the first in male and fourth in female in Ethiopia. However, there have not been studies on prognostic factors and survival of colorectal cancer. Hence, this study aimed to estimate survival time and identify prognostic factors. Methods In this institution based retrospective study, medical records review of 422 colorectal cancer patients and telephone interview was used as sources of data. Survival time was estimated using Kaplan-Meier estimator. Prognostic factors were identified using the multivariable Cox regression model. Results Patients diagnosed with rectal cancer had 76% (HR: 1.761, 95% CI: 1.173–2.644) increased risk of dying compared to colon cancer patients. Node positive patients were 3.146 (95% CI: 1.626–6.078) times likely to die compared to node-negative and metastatic cancer were 4.221 (95% CI: 2.788–6.392) times likely to die compared to non-metastatic patients. Receiving adjuvant therapy reduced the risk of death by 36.1% (HR: 0.639 (95% CI: 0.418–0.977)) compared to patients who had an only surgical resection. The median survival time was 39 months and the overall five years survival rate was 33%. Conclusions The overall survival rate was low and a majority of the patients were young at presentation. Patient’s survival is largely influenced by the advanced cancer stage at presentation and delays in the administration of adjuvant therapy. Receiving adjuvant therapy was among the good prognostic factors.

scholarly journals Prognosis of Colorectal Cancer in Tikur Anbessa Specialized Hospital, the Only Oncology Center in Ethiopia

2019 ◽  
Author(s):  
Eyob Kebede Etissa ◽  
Mathewos Assefa Assefa ◽  
Birhanu Teshome Ayele
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Adjuvant Therapy ◽  
Survival Time ◽  
Cancer Patients ◽  
Cox Regression ◽  
Addis Ababa ◽  
Specialized Hospital ◽  
Tikur Anbessa Specialized Hospital

Abstract BACKGROUND: Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females worldwide. According to Addis Ababa cancer registry, it is the first in male and fourth in female in Ethiopia. However, there have not been studies on prognostic factors and survival of colorectal cancer. Hence, this study aimed to estimate survival time and identify prognostic factors. METHODS: In this institution based retrospective study, medical records review of 422 colorectal cancer patients and telephone interview was used as sources of data. Survival time was estimated using Kaplan-Meier estimator. Prognostic factors were identified using the multivariable Cox regression model. RESULTS: The median survival time was 39 months. The overall five years survival rate was 33%. Patients diagnosed with rectal cancer had 76% (HR: 1.761, 95% CI: 1.173-2.644) increased risk to die compared to colon cancer patients. Node positive patients were 3.146 (95% CI: 1.626-6.078) times likely to die compared to node negative and metastatic cancer were 4.221 (95% CI: 2.788-6.392) times likely to die compared to non-metastatic patients. Risk of death was 36.1% lesser (HR: 0.639 (95% CI: 0.418-0.977)) among those who received adjuvant therapy compared to patients who had only surgical resection. CONCLUSION: The overall survival rate is low and majority of patients were young adults at presentation. Patient’s survival is largely influenced by advanced stage at presentation and delays in administration of adjuvant therapy. Adjuvant therapy was among the good prognostic factors. Implementation of colorectal cancer screening program and early detection with timely and advanced treatment are crucial to increase patients’ survival time. KEY WORDS: Colorectal cancer, survival, prognostic factor, Cox regression, Tikur Anbessa Specialized Hospital, Addis Ababa.

scholarly journals Prognosis of Colorectal Cancer in Tikur Anbessa Specialized Hospital, the Only Oncology Center in Ethiopia

2019 ◽  
Author(s):  
Eyob Kebede Etissa ◽  
Mathewos Assefa Assefa ◽  
Birhanu Teshome Ayele
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Adjuvant Therapy ◽  
Survival Time ◽  
Cancer Patients ◽  
Cox Regression ◽  
Addis Ababa ◽  
Specialized Hospital ◽  
Tikur Anbessa Specialized Hospital

Abstract BACKGROUND: Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females worldwide. According to Addis Ababa cancer registry, it is the first in male and fourth in female in Ethiopia. However, there have not been studies on prognostic factors and survival of colorectal cancer. Hence, this study aimed to estimate survival time and identify prognostic factors. METHODS: In this institution based retrospective study, medical records review of 422 colorectal cancer patients and telephone interview was used as sources of data. Survival time was estimated using Kaplan-Meier estimator. Prognostic factors were identified using the multivariable Cox regression model. RESULTS: The median survival time was 39 months. The overall five years survival rate was 33%. Patients diagnosed with rectal cancer had 76% (HR: 1.761, 95% CI: 1.173-2.644) increased risk to die compared to colon cancer patients. Node positive patients were 3.146 (95% CI: 1.626-6.078) times likely to die compared to node negative and metastatic cancer were 4.221 (95% CI: 2.788-6.392) times likely to die compared to non-metastatic patients. Risk of death was 36.1% lesser (HR: 0.639 (95% CI: 0.418-0.977)) among those who received adjuvant therapy compared to patients who had only surgical resection. CONCLUSION: The overall survival rate is low and majority of patients were young adults at presentation. Patient’s survival is largely influenced by advanced stage at presentation and delays in administration of adjuvant therapy. Adjuvant therapy was among the good prognostic factors. Implementation of colorectal cancer screening program and early detection with timely and advanced treatment are crucial to increase patients’ survival time. KEY WORDS: Colorectal cancer, survival, prognostic factor, Cox regression, Tikur Anbessa Specialized Hospital, Addis Ababa.

Liver metastases of colorectal carcinoma: Prospective study on the use of transarterial chemoembolization (TACE)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4062-4062
Author(s):  
T. J. Vogl ◽  
T. Gruber ◽  
S. Zangos ◽  
J. O. Balzer
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Liver Metastases ◽  
Survival Time ◽  
Cancer Patients ◽  
Median Survival ◽  
Local Control ◽  
Median Survival Time ◽  
Kaplan Meier ◽  
Colorectal Cancer Patients

4062 Background: To evaluate the efficacy of chemoembolization (TACE) in the treatment of liver metastases in colorectal cancer patients concerning local control and survival. Methods: 207 patients with liver metastases of colorectal cancer were treated with repeated TACE in 4-week intervals. In total, 1,307 chemoembolizations were performed with a mean of 6.3 sessions per patient. At the time of first chemoembolization the average age of the patients was 68.8 years (range, 39.4–83.5 years). 158 patients were treated palliatively, 35 symptomatically and 14 patients neoadjuvantly. The chemotherapy consisted of Mitomycin C with/without Gemcitabin; embolization was performed with Lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated by magnetic resonance imaging (MRI). The change in size was calculated and the response was evaluated according to the RECIST criteria. Survival rates from the first diagnosis and from the first TACE session were both calculated according to the Kaplan-Meier method to obtain the median survival. Results: While 70% of the patients showed multiple metastases, 6% had 1 metastasis, 5.8% had 2 metastases and 18.2% had 3 to 4 metastases. Lesion size and number before, during and after treatment were assessed to deduce the morphological response. Local control results according to the RECIST criteria were as follows: partial response 12% of patients, stable disease in 51% and progressive disease in 37%. The 1-year survival rate after TACE was 62%, but the 2-year survival rate had been reduced to 38%. The median survival time from the date of diagnosis of metastases was 3.4 years (according to Kaplan-Meier), the median survival time from the start of TACE treatment was 1.34 years. The median survival time of the palliative group was 1.4 years, of the symptomatic group 0.8 years and of the neoadjuvant group 1.5 years. Conclusions: TACE is an effective minimal-invasive therapy for neoadjuvant, symptomatic or palliative treatment of liver metastases in colorectal cancer patients. No significant financial relationships to disclose.

The impact of guideline treatment nonadherence on survival for colorectal cancer patients: Propensity score calibration via a validation cohort.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 308-308
Author(s):  
Robert Brooks Hines ◽  
Sue Min Lai ◽  
Joaquina Celebre Baranda ◽  
Kimberly K. Engelman ◽  
Frank Dong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Propensity Score ◽  
Cancer Patients ◽  
Validation Cohort ◽  
Treatment Guidelines ◽  
Risk Of Death ◽  
Increased Risk ◽  
The Impact

308 Background: The quality of cancer care has been the focus of ongoing concern for cancer researchers, providers, and policy makers. The objectives of this study were: 1) to evaluate nonadherence with National Comprehensive Cancer Network treatment guidelines for colorectal cancer (CRC) patients and the impact on survival, and 2) to obtain error-corrected estimates of effect by means of propensity score calibration via a validation cohort. Methods: CRC patients identified by the Georgia Comprehensive Cancer Registry for the years 2000-07 were eligible (N = 18,388). Naïve propensity score (PSn) adjustment and PS calibration (PSC) via a validation cohort were utilized to obtain hazard ratio estimates for the impact of guideline treatment nonadherence on 5-year overall survival. The validation cohort contained additional information on comorbidity and payer status which was used to obtain error-corrected estimates of effect by PSC. Results: Treatment nonadherence conferred a large increased risk of death early in the follow-up period which declined over time (Table 1). Comparison of results from the PSn and PSC models indicated moderate to large bias due to unmeasured confounding in the PSn model (data not shown). Conclusions: PSC produced attenuated estimates and had an impact on study conclusions in the latter follow-up period. For CRC patients, health services research into the quality of care received by cancer patients is necessary to continue the improving trend in CRC-related mortality. [Table: see text]

The survival rate and prognostic factors in 26 perforated colorectal cancer patients

2006 ◽  
Vol 22 (5) ◽  
pp. 467-473 ◽  
Author(s):  
In Kyu Lee ◽  
Na Young Sung ◽  
Yoon Suk Lee ◽  
Sang Chul Lee ◽  
Won Kyung Kang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Cancer Patients ◽  
Perforated Colorectal Cancer ◽  
Colorectal Cancer Patients

scholarly journals Survival Rate of Colorectal Cancer and Its Effective Factors in Iran

2021 ◽  
Author(s):  
Mohammad Abbasi ◽  
Saeedeh Asgari ◽  
Azar Pirdehghan ◽  
Abdol Azim Sedighi Pashaki ◽  
Farzaneh Esna-Ashari
Keyword(s):  
Colorectal Cancer ◽  
Survival Rate ◽  
Cox Regression ◽  
Survival Rates ◽  
Early Screening ◽  
Cox Regression Analysis ◽  
Effective Factors ◽  
Risk Of Death ◽  
Phone Calls ◽  
Increased Risk

Colorectal cancer is one of the most common cancers in Iran. Regarding the prevalence of this cancer and its mortality and morbidity, in this study, 5 Year Survival Rate and its Effective Factors of patients with colorectal cancer were investigated. This study was conducted using the retrospective cohort method. All patients diagnosed with colorectal cancer in Hamadan Imam Khomeini Clinic of Hematology and Oncology and Mahdieh Oncology Center between 2006 and 2011 were studied. Data were extracted from the patients’ medical records, and to obtain extra information about them, telephone calls were made. The data were analyzed by SPPS version 16, and the assessment of survival rates was conducted using Kaplan-Meier methods and Cox regression method. A total number of 108 patients with colorectal cancer were studied. The status of 74 patients was determined at the end of the study by making follow-up phone calls. The one, two, three, four, and five survival rates were 77, 66, 50, 45, and 42%, respectively. The median overall survival was 46.8 months (1.3-135.6 months). Cox regression analysis showed that Metastatic tumor (P=0.001), lymphatic involvement (P=0.043), and is associated with underlying disease (P=0.025) was accompanied by increased risk. Multivariate cox regression test showed that metastasis was associated with an increase in the risk of death significantly (HR=2.83, P=0.013). According to the findings of the study, early screening is recommended for people with greater risk to increase the survival rate.

scholarly journals Prognostic Factors and Overall Survival After Pericardiocentesis in Patients With Cancer and Thrombocytopenia

2021 ◽  
Vol 8 ◽  
Author(s):  
Nathaniel R. Wilson ◽  
Michelle T. Lee ◽  
Clarence D. Gill ◽  
Astrid Serauto Canache ◽  
Teodora Donisan ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Pericardial Effusion ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Univariate Analysis ◽  
Severe Thrombocytopenia ◽  
Complication Rates ◽  
Risk Of Death ◽  
Increased Risk

Background: Pericardiocentesis is an important diagnostic and therapeutic tool for cancer-associated pericardial effusion. Limited safety and outcomes data exists regarding the management of malignancy-related pericardial effusion in patients with thrombocytopenia.Objectives: Our study aimed to analyze prognostic factors and overall survival (OS) after pericardiocentesis in thrombocytopenic cancer patients.Methods and Results: A retrospective review of 136 thrombocytopenic cancer patients who underwent primary percutaneous pericardiocentesis was performed. Degree of thrombocytopenia was classified by platelet count recorded on day of pericardiocentesis: 75–149 × 103 cells/μL (41%); 50–74 × 103 cells/μL (10%); 25–49 × 103 cells/μL (24%); <25 × 103 cells/μL (25%). Median OS was 2.6 months and median follow-up was 37.4 months. Kaplan-Meier survival analysis showed significant OS differences among thrombocytopenia severity groups (p = 0.023), and worse OS with platelets <100 vs. ≥100 × 103 cells/μL (p = 0.031). By univariate analysis, thrombocytopenia severity was associated with increased risk of death (HR 0.993; 95% CI 0.989–0.997; p = 0.002). Poor prognostic factors for OS were advanced cancer, malignant effusion, elevated international normalized ratio (INR), quantity of platelet transfusions, and platelet transfusion resistance. However, thrombocytopenia severity became insignificant for OS (p = 0.802), after adjusting for advanced cancer and INR.Conclusions: For patients with malignancy-related large pericardial effusion and thrombocytopenia, pericardiocentesis is a feasible intervention and should be considered due to low complication rates. There is no absolute contraindication to pericardiocentesis in case of hemodynamic instability, even with severe thrombocytopenia.

Prognostic Factors in the Survival Rate of colorectal cancer patients

2015 ◽  
Vol 7 (1) ◽  
pp. 45-53 ◽  
Author(s):  
R Parsaee ◽  
N Fekri ◽  
S Shahid sales ◽  
M AfzalAghaee ◽  
E Shaarbaf Eidgahi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Survival Rate ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

COVID-19 disease in patients with LUNG cancer in Spain: GRAVID LunG canceR pAtients coVid19 Disease (GRAVID STUDY).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18709-e18709
Author(s):  
Mariano Provencio ◽  
Jose Maria Mazarico ◽  
Antonio Calles ◽  
Monica Antoñanzas ◽  
Cristina Pangua ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Life Stage ◽  
Logistic Regression Models ◽  
Lung Cancer Patients ◽  
Risk Of Death ◽  
Increased Risk ◽  
Anticancer Treatment ◽  
Ventilation Rates

e18709 Background: Patients with cancer may be more susceptible to infection and at increased risk of more severe COVID-19 disease; however, prognostic factors are not yet clearly identified. The LunG canceR pAtients coVid19 Disease (GRAVID) study aimed to describe clinical characteristics, outcomes, and predictors of poor outcome in patients with lung cancer and COVID-19. Methods: In this large nationwide study, we reviewed medical records of patients with lung cancer and confirmed COVID-19 diagnosis from 65 Spanish hospitals. Clinical features, treatments and disease outcomes were collected. The primary endpoint was to determine all-cause mortality; secondary endpoints were hospitalization and admission to intensive care units (ICU). Risk factors for poor prognosis were identified by univariate and multivariate logistic regression models. Results: Overall, 447 patients were included for analysis. Mean age was 67·1 ± 9·8 years; 332 (74·3%) were men, and 383 (85·7%) current/former smokers. NSCLC was the most frequent type of cancer (377, 84·5%), consisting mainly of adenocarcinoma (228, 51·0%), and stage III metastatic or unresectable disease (354, 79·2%). Two-hundred and sixty-six (59·5%) patients were receiving anticancer treatment, mostly first-line chemotherapy. In total, 350 (78·3%) patients were hospitalized for a mean of 13·4 ± 11·4 days, nine (2·0%) patients were admitted to the ICU, and 146 (32·7%) died. Advanced disease and the use of corticosteroids to treat COVID-19 during hospitalization were predictors of mortality. Hospitalized, non-end-of-life stage patients with lymphocytopenia and high LDH had an increased risk of death. Severity of COVID-19 correlated to higher mortality, ICU admission, and mechanical ventilation rates. Conclusions: Due to their underlying comorbidities and immunocompromised status, patients with lung cancer and COVID-19 show high hospitalization and mortality rates. These outcomes, alongside the identification of prognostic factors, may inform physicians on the risks and benefits in this population, in order to provide individualized oncological care.

Sign in / Sign up

Export Citation Format

Share Document